CY1108998T1 - Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις - Google Patents
Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχειςInfo
- Publication number
- CY1108998T1 CY1108998T1 CY20071100833T CY071100833T CY1108998T1 CY 1108998 T1 CY1108998 T1 CY 1108998T1 CY 20071100833 T CY20071100833 T CY 20071100833T CY 071100833 T CY071100833 T CY 071100833T CY 1108998 T1 CY1108998 T1 CY 1108998T1
- Authority
- CY
- Cyprus
- Prior art keywords
- osteoprotein
- binding
- receptors
- treatment
- production
- Prior art date
Links
- 102000008108 Osteoprotegerin Human genes 0.000 title 1
- 108010035042 Osteoprotegerin Proteins 0.000 title 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 3
- 108091008324 binding proteins Proteins 0.000 abstract 3
- 208000020084 Bone disease Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 238000000159 protein binding assay Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
Abstract
Ένα πρωτότυπο πολυπεπτίδιο, πρωτεΐνη που δεσμεύεται με οστεοπροτεγερίνη, που εμπλέκεται σε ωρίμανση οστεοκλαστών, ταυτοποιήθηκε με βάση την συγγένεια του για οστεοπροτεγερίνη. Περιγράφονται επίσης αλληλουχίες νουκλεϊκών οξέων που κωδικοποιούν το πολυπεπτίδιο, ή θραύσμα, ανάλογο ή παράγωγο αυτού, φορείς και κύτταρα-ξενιστές για παραγωγή, μέθοδοι παρασκευής πρωτεΐνης που δεσμεύεται με οστεοπροτεγερίνη, και προσδιορισμοί δέσμευσης. Παρέχονται επίσης συνθέσεις και μέθοδοι για την θεραπευτική αγωγή ασθενειών οστών όπως οστεοπόρωση, απώλεια οστού λόγω αρθρίτιδας ή μετάστασης, υπερασβεστιαιμία, και νόσος Paget. Περιγράφονται επίσης υποδοχείς για πρωτεΐνες που δεσμεύονται με οστεοπροτεγερίνη. Οι υποδοχείς, και αγωνιστές και ανταγωνιστές αυτών, μπορούν να χρησιμοποιηθούν για θεραπευτική αγωγή ασθενειών οστών.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/842,842 US5843678A (en) | 1997-04-16 | 1997-04-16 | Osteoprotegerin binding proteins |
US88085597A | 1997-06-23 | 1997-06-23 | |
US09/052,521 US6316408B1 (en) | 1997-04-16 | 1998-03-30 | Methods of use for osetoprotegerin binding protein receptors |
EP98918244.9A EP0975754B2 (en) | 1997-04-16 | 1998-04-15 | Osteoprotegerin binding proteins and their receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108998T1 true CY1108998T1 (el) | 2014-07-02 |
Family
ID=27126366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100833T CY1108998T1 (el) | 1997-04-16 | 2007-06-21 | Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις |
Country Status (15)
Country | Link |
---|---|
US (4) | US6316408B1 (el) |
EP (1) | EP2311955A3 (el) |
JP (2) | JP2009001566A (el) |
KR (2) | KR101328809B1 (el) |
CN (1) | CN103990122B (el) |
CA (1) | CA2706609A1 (el) |
CY (1) | CY1108998T1 (el) |
GE (1) | GEP20033002B (el) |
IL (1) | IL132304A (el) |
LT (1) | LTC0975754I2 (el) |
ME (2) | MEP32808A (el) |
NO (1) | NO2010022I2 (el) |
PT (1) | PT975754E (el) |
RO (1) | RO122495B1 (el) |
RS (1) | RS50358B (el) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
AU5697098A (en) * | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP2314695A3 (en) * | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
DE122010000049I1 (de) * | 1997-04-15 | 2011-05-05 | Daiichi Sankyo Co Ltd | Neues protein und verfahren zu dessen herstellung |
CZ302262B6 (cs) | 1997-04-16 | 2011-01-19 | Amgen Inc. | Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
ES2317694T3 (es) * | 1998-05-14 | 2009-04-16 | Immunex Corporation | Metodo para inhibir la actividad osteoclastica. |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
DE60129254T2 (de) * | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
PL361909A1 (en) * | 2001-02-06 | 2004-10-04 | The Royal Alexandra Hospital For Children | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
AU2002231602A1 (en) * | 2001-02-09 | 2002-08-28 | Maxygen Holdings Ltd. | Rank ligand-binding polypeptides |
US20040132971A1 (en) * | 2001-02-09 | 2004-07-08 | Haaning Jesper Mortensen | Rank ligand-binding polypeptides |
EP1432438A2 (en) * | 2001-06-06 | 2004-06-30 | Immunex Corporation | Use of rank antagonists to treat cancer |
KR20040023630A (ko) | 2001-06-26 | 2004-03-18 | 아브게닉스, 인크. | Opgl에 결합하는 항체 |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
US20030109444A1 (en) * | 2001-10-12 | 2003-06-12 | Jonathan Lam | Bone anti-resorptive compounds |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
US7381792B2 (en) * | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
US20040170602A1 (en) * | 2002-01-04 | 2004-09-02 | Desjarlais John R. | Dominant negative proteins and methods thereof |
EP1576088A4 (en) * | 2002-01-04 | 2006-09-06 | Xencor Inc | DOMINANT NEGATIVE PROTEINS AND METHOD THEREFOR |
US7718776B2 (en) | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
MXPA05006147A (es) * | 2002-12-10 | 2005-08-26 | Schering Plough Ltd | Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo. |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
BRPI0519008A2 (pt) * | 2004-12-13 | 2008-12-23 | Evogenix Ltd | proteÍnas variantes de osteoprotegerina |
AR056806A1 (es) * | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
US8101564B2 (en) * | 2006-05-03 | 2012-01-24 | Trustees Of The University Of Pennsylvania | Methods for regulating osteoclast differentiation and bone resorption using LRRc17 |
WO2008088594A2 (en) * | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
JP5191487B2 (ja) * | 2007-06-05 | 2013-05-08 | オリエンタル酵母工業株式会社 | 新しい骨量増加薬 |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
CN108192972B (zh) | 2010-10-06 | 2022-09-09 | 生物医学研究机构基金会 | 用于乳腺癌转移的诊断、预后和治疗的方法 |
HUE052094T2 (hu) * | 2011-04-19 | 2021-04-28 | Amgen Inc | Osteoporosis kezelési módszere |
GB201118840D0 (en) | 2011-11-01 | 2011-12-14 | Univ Sheffield | Pulmonary hypertension II |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
KR101872965B1 (ko) | 2012-10-12 | 2018-06-29 | 인바이오모션 에스.엘. | C―maf를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
JP6577873B2 (ja) | 2013-03-15 | 2019-09-18 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) | がんの転移の予後診断および処置のための方法 |
MX2016002870A (es) | 2013-09-05 | 2017-02-23 | Amgen Inc | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. |
CA2926894A1 (en) | 2013-10-09 | 2015-04-16 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer |
US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ.エレ. | ヒトc−mafに対する結合メンバー |
MX2017013802A (es) | 2015-04-29 | 2018-08-15 | Radius Pharmaceuticals Inc | Métodos para tratar el cáncer. |
CN117230193A (zh) | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
RU2022108295A (ru) | 2016-06-22 | 2022-04-06 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
KR102557321B1 (ko) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
WO2018138297A1 (en) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anti-opg antibodies |
MA47775A (fr) | 2017-03-14 | 2020-01-22 | Amgen Inc | Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
CA3082728A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
BR112020019559A2 (pt) | 2018-03-26 | 2021-01-12 | Amgen Inc. | Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células |
EP3817821A1 (en) | 2018-07-04 | 2021-05-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
TWI679439B (zh) * | 2018-10-01 | 2019-12-11 | 緯穎科技服務股份有限公司 | 電源管理系統及電源管理方法 |
AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
EP4110371A1 (en) | 2020-01-24 | 2023-01-04 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US595524A (en) * | 1897-12-14 | William clough | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
EP0192658A4 (en) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | RETROVIRAL GENE TRANSFER VECTORS. |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2071912C (en) | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
MX9204303A (es) | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH07509223A (ja) | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5578569A (en) | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69427588T2 (de) | 1993-09-14 | 2002-04-25 | Merck & Co Inc | HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5641747A (en) * | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
EP0792278B1 (en) | 1994-11-07 | 2007-06-13 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
EP0727211A1 (en) | 1995-02-10 | 1996-08-21 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
US20030166097A1 (en) | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
WO1996034095A1 (en) | 1995-04-27 | 1996-10-31 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
AU6090896A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5763223A (en) | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US5981220A (en) | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
AU5697098A (en) | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
FR2757507B1 (fr) | 1996-12-20 | 1999-01-29 | Inst Francais Du Petrole | Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation |
EP0951546A2 (en) | 1996-12-20 | 1999-10-27 | The Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
EP2314695A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
DE122010000049I1 (de) * | 1997-04-15 | 2011-05-05 | Daiichi Sankyo Co Ltd | Neues protein und verfahren zu dessen herstellung |
CZ302262B6 (cs) | 1997-04-16 | 2011-01-19 | Amgen Inc. | Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající |
US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
CA2229449A1 (en) * | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
JP2002514079A (ja) | 1997-05-01 | 2002-05-14 | アムジエン・インコーポレーテツド | キメラopgポリペプチド |
AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
JPH119269A (ja) * | 1997-06-19 | 1999-01-19 | Kaken Pharmaceut Co Ltd | 破骨細胞系細胞 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
US7063960B2 (en) * | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
ES2317694T3 (es) | 1998-05-14 | 2009-04-16 | Immunex Corporation | Metodo para inhibir la actividad osteoclastica. |
HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
IL141588A0 (en) * | 1998-09-15 | 2002-03-10 | M & E Biotech As | Method for down-regulating osteoprotegerin ligand activity |
AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
EP1140136B1 (en) | 1999-09-03 | 2007-05-16 | Amgen Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
WO2001062932A1 (en) | 2000-02-23 | 2001-08-30 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
US20040247596A1 (en) | 2000-08-18 | 2004-12-09 | Odgren Paul R. | TRANCE regulation of chondrocyte differentiation |
WO2002015846A2 (en) | 2000-08-21 | 2002-02-28 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
DE60129254T2 (de) | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
JP2004536056A (ja) | 2001-05-17 | 2004-12-02 | イミュネックス・コーポレーション | Rankアンタゴニストの療法使用 |
EP1432438A2 (en) | 2001-06-06 | 2004-06-30 | Immunex Corporation | Use of rank antagonists to treat cancer |
KR20040023630A (ko) | 2001-06-26 | 2004-03-18 | 아브게닉스, 인크. | Opgl에 결합하는 항체 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US7183069B2 (en) | 2002-03-07 | 2007-02-27 | Toyama University | Reagent, method and apparatus for measuring amylase activity |
US7718776B2 (en) | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
US7504586B2 (en) | 2002-11-27 | 2009-03-17 | Yazaki Corporation | Cable and cable identificating method |
-
1998
- 1998-03-30 US US09/052,521 patent/US6316408B1/en not_active Expired - Lifetime
- 1998-04-15 ME MEP-328/08A patent/MEP32808A/xx unknown
- 1998-04-15 GE GEAP19985034A patent/GEP20033002B/en unknown
- 1998-04-15 CN CN201310463795.5A patent/CN103990122B/zh not_active Expired - Lifetime
- 1998-04-15 ME MEP-2008-328A patent/ME00184B/me unknown
- 1998-04-15 RS YUP-506/99A patent/RS50358B/sr unknown
- 1998-04-15 PT PT98918244T patent/PT975754E/pt unknown
- 1998-04-15 CA CA2706609A patent/CA2706609A1/en not_active Abandoned
- 1998-04-15 KR KR1020127021477A patent/KR101328809B1/ko not_active IP Right Cessation
- 1998-04-15 KR KR1019997009492A patent/KR101314478B1/ko not_active IP Right Cessation
- 1998-04-15 EP EP10184791A patent/EP2311955A3/en not_active Withdrawn
- 1998-04-15 RO RO99-01101A patent/RO122495B1/ro unknown
- 1998-12-14 US US09/211,315 patent/US7097834B1/en not_active Expired - Lifetime
- 1998-12-14 US US09/211,297 patent/US7807795B2/en not_active Expired - Fee Related
-
1999
- 1999-10-08 IL IL132304A patent/IL132304A/en active Protection Beyond IP Right Term
-
2004
- 2004-04-15 US US10/825,898 patent/US20050003400A1/en not_active Abandoned
-
2007
- 2007-06-21 CY CY20071100833T patent/CY1108998T1/el unknown
-
2008
- 2008-06-11 JP JP2008153218A patent/JP2009001566A/ja not_active Withdrawn
-
2010
- 2010-11-24 LT LTPA2010013C patent/LTC0975754I2/lt unknown
- 2010-11-25 NO NO2010022C patent/NO2010022I2/no unknown
-
2012
- 2012-09-13 JP JP2012201172A patent/JP2013028622A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL132304A (en) | 2015-07-30 |
US6316408B1 (en) | 2001-11-13 |
ME00184B (me) | 2010-10-10 |
GEP20033002B (en) | 2003-06-25 |
JP2009001566A (ja) | 2009-01-08 |
KR20120108046A (ko) | 2012-10-04 |
KR101328809B1 (ko) | 2014-01-17 |
CN103990122A (zh) | 2014-08-20 |
US7097834B1 (en) | 2006-08-29 |
US20030100488A1 (en) | 2003-05-29 |
YU50699A (sh) | 2000-10-30 |
US7807795B2 (en) | 2010-10-05 |
LTC0975754I2 (lt) | 2022-03-25 |
EP2311955A2 (en) | 2011-04-20 |
NO2010022I1 (no) | 2011-01-10 |
KR20010006405A (ko) | 2001-01-26 |
JP2013028622A (ja) | 2013-02-07 |
CA2706609A1 (en) | 1998-10-22 |
LTPA2010013I1 (lt) | 2021-05-25 |
KR101314478B1 (ko) | 2014-01-17 |
EP2311955A3 (en) | 2012-12-12 |
RO122495B1 (ro) | 2009-07-30 |
NO2010022I2 (no) | 2015-03-30 |
RS50358B (sr) | 2009-11-10 |
MEP32808A (en) | 2010-10-10 |
CN103990122B (zh) | 2017-01-04 |
US20050003400A1 (en) | 2005-01-06 |
PT975754E (pt) | 2007-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108998T1 (el) | Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις | |
EA199900939A1 (ru) | Остеопротегерин-связывающие белки и рецепторы | |
CY1119263T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων | |
EA200100447A1 (ru) | Гибридные белки на основе бета-интерферона и их применение | |
CY1111097T1 (el) | Πρωτεϊνη δεσμευσης του υποδοχεα nogo | |
CY1105895T1 (el) | Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης | |
CY1111006T1 (el) | Εκριμματαση ασθενειας alzheimer | |
ATE490323T1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
CY1108083T1 (el) | Αντιγονα και συνθεσεις του neisseria meningitidis | |
ATE336578T1 (de) | Nukleinsäurebindungsproteine | |
CY1112101T1 (el) | Νευροτροφικοι παραγοντες | |
ATE449850T1 (de) | Mutanten von flt3-l und ihre verwendungen | |
FI961251A0 (fi) | Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet | |
CY1108545T1 (el) | Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι | |
BR9811039A (pt) | Citocina de mamìferos: interleucina-b30 e reagentes relacionados | |
FI962247A (fi) | Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät | |
CY1109093T1 (el) | Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι | |
BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
DE68925275D1 (de) | Endotoxin-bindeprotein und dessen verwendung | |
DK1576157T3 (da) | Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme | |
SE9602822D0 (sv) | New receptor | |
MXPA02009791A (es) | El gen de alta masa osea de 11q13.3. | |
EP1964921A3 (en) | The high bone mass gene of 11q13.3 | |
SE9604439D0 (sv) | New receptor | |
HUP0100780A2 (hu) | Új dezintegrin metalloproteáz, mutánsai, fragmentumai és hasonlók alkalmazása |